Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine
Portfolio Pulse from Vandana Singh
Merck & Co Inc has announced positive results from two Phase 3 trials for its investigational 21-valent pneumococcal conjugate vaccine, V116. The vaccine showed statistically significant immune responses compared to PCV20 in vaccine-naïve adults and was immunogenic for all 21 pneumococcal serotypes in adults who had received a pneumococcal vaccine at least a year before the study. The safety profile of V116 was comparable to the comparator.
July 27, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's positive trial results for its V116 vaccine could potentially boost investor confidence in the company's product pipeline. However, the company's shares are currently down by 0.88%.
The positive trial results for Merck's V116 vaccine indicate progress in the company's product pipeline, which could potentially attract investors. However, the current decrease in the company's share price suggests that the market has not yet fully absorbed this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100